Hamman-Rich syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(7 intermediate revisions by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
There is no effective treatment for acute interstitial pneumonitis, includes supportive therapy and glucocorticosteroids.  
There is no effective treatment for [[Hamman-Rich syndrome|acute interstitial pneumonitis]], Management in general includes supportive therapy and administration of glucocorticosteroids and Immunosuppressive agents.  
==Supportive care==
==Supportive care==
*Patients with acute interstitial pneumonitis receive supportive care alongside the medical therapy:
*Patients with [[Hamman-Rich syndrome|acute interstitial pneumonitis]] receive supportive care alongside the medical therapy<ref name="pmid16537878">{{cite journal |vauthors=Suh GY, Kang EH, Chung MP, Lee KS, Han J, Kitaichi M, Kwon OJ |title=Early intervention can improve clinical outcome of acute interstitial pneumonia |journal=Chest |volume=129 |issue=3 |pages=753–61 |date=March 2006 |pmid=16537878 |doi=10.1378/chest.129.3.753 |url=}}</ref>:
**Supplemental oxygen
**Supplemental [[oxygen]]
**Mechanical ventilation
**[[Mechanical ventilation]]
**Measures to be taken to relieve [[Symptom|symptoms]] (eg, [[dyspnea]], [[anxiety]], [[cough]])
**Prevention of complications  
**Prevention of complications  
***Venous thromboembolism
***[[Venous thromboembolism]]
***Gastrointestinal bleeding
***[[Gastrointestinal bleeding]]
*** Hospital-acquired pneumonia
*** [[Hospital-acquired pneumonia]]
***Sepsis
*** Secondary [[pulmonary hypertension]]
*Pulmonary rehabilitation
*** [[Anemia]]
*Vaccination against possible causes of pulmonary inflammation as influenza and pneumococcal vaccines.
***[[Sepsis]]
*Pulmonary rehabilitation (eg, patient education, optimal exercise program)
*Maintain ideal body-mass index
**Reduction of weight if obese
**Nutritional support if the patient is cachectic
*[[Vaccination]] against possible causes of pulmonary inflammation as [[influenza]] and [[Streptococcus pneumoniae|pneumococca]]<nowiki/>l vaccines.<ref name="pmid25233284">{{cite journal |vauthors=Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T |title=Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP) |journal=MMWR Morb. Mortal. Wkly. Rep. |volume=63 |issue=37 |pages=822–5 |date=September 2014 |pmid=25233284 |pmc=5779453 |doi= |url=}}</ref>
==Medical Therapy==
==Medical Therapy==
*Corticosteroid therapy:
*Corticosteroid therapy:<ref name="pmid19095855">{{cite journal |vauthors=Avnon LS, Pikovsky O, Sion-Vardy N, Almog Y |title=Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations |journal=Anesth. Analg. |volume=108 |issue=1 |pages=232–7 |date=January 2009 |pmid=19095855 |doi=10.1213/ane.0b013e318188af7a |url=}}</ref>
**Once the diagnosis of acute interstitial pneumonitis is confirmed, high doses of glucocorticosteroids (eg, methylprednisolone)  should be administered.
**Once the [[diagnosis]] of [[Hamman-Rich syndrome|acute interstitial pneumonitis]] is confirmed, high doses of [[Steroid|glucocorticosteroids]] (eg, [[methylprednisolone]])  should be administered.
**Monitor the patient for glucocorticosteroid-induced side effects (eg, hyperglycemia, increased susceptibility to infection, gastritis).
**Monitor the patient for glucocorticosteroid-induced side effects (eg, [[hyperglycemia]], increased susceptibility to [[infection]], [[gastritis]]).
*Immunosuppressive therapy
*Immunosuppressive therapy


==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}


[[Category:Pulmonology]]
[[Category:Pulmonology]]

Latest revision as of 17:04, 23 March 2018

Hamman-Rich syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hamman-Rich syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hamman-Rich syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hamman-Rich syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hamman-Rich syndrome medical therapy

CDC on Hamman-Rich syndrome medical therapy

Hamman-Rich syndrome medical therapy in the news

Blogs on Hamman-Rich syndrome medical therapy

Directions to Hospitals Treating Hamman-Rich syndrome

Risk calculators and risk factors for Hamman-Rich syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]

Overview

There is no effective treatment for acute interstitial pneumonitis, Management in general includes supportive therapy and administration of glucocorticosteroids and Immunosuppressive agents.

Supportive care

Medical Therapy


References

  1. Suh GY, Kang EH, Chung MP, Lee KS, Han J, Kitaichi M, Kwon OJ (March 2006). "Early intervention can improve clinical outcome of acute interstitial pneumonia". Chest. 129 (3): 753–61. doi:10.1378/chest.129.3.753. PMID 16537878.
  2. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T (September 2014). "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Morb. Mortal. Wkly. Rep. 63 (37): 822–5. PMC 5779453. PMID 25233284.
  3. Avnon LS, Pikovsky O, Sion-Vardy N, Almog Y (January 2009). "Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations". Anesth. Analg. 108 (1): 232–7. doi:10.1213/ane.0b013e318188af7a. PMID 19095855.

Template:WH Template:WS